[go: up one dir, main page]

AR126196A1 - Proceso para preparar inhibidores de egfr - Google Patents

Proceso para preparar inhibidores de egfr

Info

Publication number
AR126196A1
AR126196A1 ARP220101628A ARP220101628A AR126196A1 AR 126196 A1 AR126196 A1 AR 126196A1 AR P220101628 A ARP220101628 A AR P220101628A AR P220101628 A ARP220101628 A AR P220101628A AR 126196 A1 AR126196 A1 AR 126196A1
Authority
AR
Argentina
Prior art keywords
prepare
egfr inhibitors
compound
producing
present disclosure
Prior art date
Application number
ARP220101628A
Other languages
English (en)
Inventor
Erika Lee Christopher Maceachern Lauren Waetzig Joshua D Butler
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of AR126196A1 publication Critical patent/AR126196A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación proporciona métodos para producir un compuesto de fórmula (1) estructural, o una sal farmacéuticamente aceptable de este.
ARP220101628A 2021-06-23 2022-06-22 Proceso para preparar inhibidores de egfr AR126196A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163214069P 2021-06-23 2021-06-23

Publications (1)

Publication Number Publication Date
AR126196A1 true AR126196A1 (es) 2023-09-27

Family

ID=82655383

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101628A AR126196A1 (es) 2021-06-23 2022-06-22 Proceso para preparar inhibidores de egfr

Country Status (10)

Country Link
US (1) US20240300922A1 (es)
EP (1) EP4359401A1 (es)
JP (1) JP2024524246A (es)
CN (1) CN117881670A (es)
AR (1) AR126196A1 (es)
AU (1) AU2022299172A1 (es)
CA (1) CA3223412A1 (es)
IL (1) IL309465A (es)
TW (1) TW202317542A (es)
WO (1) WO2022271801A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023012060A (es) 2021-04-13 2024-01-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr.
CN116554150B (zh) * 2022-12-30 2025-12-19 苏州浦合医药科技有限公司 第四代egfr抑制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4092992B2 (ja) * 2001-09-13 2008-05-28 ダイソー株式会社 ｃｉｓ−アミノインダノール誘導体、その製法およびその使用
ES2244314B1 (es) * 2004-02-17 2007-02-01 Laboratorios Del Dr. Esteve, S.A. Compuestos azetidinicos sustituidos, su preparacion y su aplicacion como medicamentos.
UY33758A (es) * 2010-12-01 2012-06-29 Boehringer Ingelheim Int Acidos indaniloxidihidrobenzofuranilaceticos
HUE053645T2 (hu) * 2013-11-18 2021-07-28 Forma Therapeutics Inc Tetrahidrokinolin kompozíciók mint BET bromodomén inhibitorok
TWI726968B (zh) * 2016-01-07 2021-05-11 開曼群島商Ｃｓ醫藥技術公司 Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
CN112638381B (zh) * 2018-09-04 2024-08-30 康蒂内乌姆医疗公司 毒蕈碱性乙酰胆碱m1受体拮抗剂
TW202235416A (zh) * 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
CN115135642B (zh) * 2019-12-23 2025-03-04 缆图药品公司 Egfr突变形式的抑制剂

Also Published As

Publication number Publication date
CA3223412A1 (en) 2022-12-29
TW202317542A (zh) 2023-05-01
EP4359401A1 (en) 2024-05-01
AU2022299172A1 (en) 2024-01-18
JP2024524246A (ja) 2024-07-05
US20240300922A1 (en) 2024-09-12
CN117881670A (zh) 2024-04-12
WO2022271801A1 (en) 2022-12-29
IL309465A (en) 2024-02-01

Similar Documents

Publication Publication Date Title
MX2022007969A (es) Inhibidores de egfr.
MX2025008591A (es) Inhibidores de cdk
MX2024000230A (es) Inhibidores de cdk2.
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
CO2024001367A2 (es) Compuestos antivirales
UY38057A (es) Inhibidores de sarcómero cardíaco
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
MX2021011606A (es) Compuestos dirigidos a prmt5.
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
MX2021000348A (es) 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo.
CL2021002575A1 (es) Compuestos de pirrol
AR126196A1 (es) Proceso para preparar inhibidores de egfr
MX2024012267A (es) Inhibidores de egfr
CO2021017202A2 (es) Compuestos tricíclicos
MX2025003091A (es) Metodo para producir derivado de heterociclideno acetamida
AR130287A1 (es) Métodos para la fabricación de inhibidores de quinasa
CL2022003008A1 (es) Procesos para la preparación de un inhibidor de cinasa
UY39662A (es) Inhibidores de egfr
MX2022002720A (es) Inhibidor de magl, procedimiento de preparacion y uso del mismo.
EA202192051A1 (ru) Селективный ингибитор протеин-аргинин-метилтрансферазы 5 (prmt5)
MX2021014245A (es) Procedimientos y productos intermedios para preparar un inhibidor de btk.

Legal Events

Date Code Title Description
FB Suspension of granting procedure